A11100P

N6-benzoyl-2'-deoxy-5'-O-(4,4'-dimethoxytrityl)adenosine 3'-(2-cyanoethyle diisopropylphosphoramidite)

• Synonyme(s) : Adenosine, N-benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxy-, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite], Adenosine, N-benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxy-, 3′-[2-cyanoethyl bis(1-methylethyl)phosphoramidite], DMT-dA(bz) Phosphoramidite, N-benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyadenosine, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite], N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine-3′-O-[O-(2-cyanoethyl)-N,N′-diisopropylphosphoramidite]
• Formule empirique (notation de Hill): C₄₇H₅₂N₇O₇P
• Numéro CAS: 98796-53-3
• Poids moléculaire : 857.93
• Numéro MDL: MFCD00036314
• Code UNSPSC : 41116107
• ID de substance PubChem : 329770659
• Nomenclature NACRES : NA.51

Propriétés

• Source biologique: non-animal source (no BSE/TSE risk)
• Niveau de qualité: 300
• Type: for DNA synthesis
• Gamme de produits: Proligo Reagents
• Essai: ≥99.5% (reversed phase HPLC); >99.5% (³¹P-NMR)
• Forme: powder or granules
• Technique(s): oligo synthesis: suitable
• Impuretés: >= 170ppm, none detected (S/N <2.5); ≤0.1% P(III) 100-169ppm (³¹P-NMR); ≤0.1% single unspecified Imprity (reversed phase HPLC); ≤0.3% dA2 (reversed phase HPLC, DMT-dA(bz) cyanoethyl-H-posphonate); ≤0.3% dA3 (reversed phase HPLC, DMT-dA(bz) phosphoramidate); ≤0.30 wt. % water content (Karl Fischer); ≤0.5% P(V) -25-99ppm (³¹P-NMR); ≤3.0 wt. % residual solvent content
• Couleur: white to off-white
• Solubilité: soluble, clear
• Adéquation: conforms to structure for H-NMR; conforms to structure for LC-MS
• Profil des nucléosides: base: deoxyadenosine; base protecting group: benzoyl; 2' protecting group: none; 5' protecting group: DMT; deprotection: standard
• Température de stockage: 2-8°C
• Chaîne SMILES: COc1ccc(cc1)C(OC[C@H]2O[C@H](C[C@@H]2OP(OCCC#N)N(C(C)C)C(C)C)n3cnc4c(NC(=O)c5ccccc5)ncnc34)(c6ccccc6)c7ccc(OC)cc7
• InChI: 1S/C47H52N7O7P/c1-32(2)54(33(3)4)62(59-27-13-26-48)61-40-28-42(53-31-51-43-44(49-30-50-45(43)53)52-46(55)34-14-9-7-10-15-34)60-41(40)29-58-47(35-16-11-8-12-17-35,36-18-22-38(56-5)23-19-36)37-20-24-39(57-6)25-21-37/h7-12,14-25,30-33,40-42H,13,27-29H2,1-6H3,(H,49,50,52,55)/t40-,41+,42+,62?/m0/s1
• Clé InChI: GGDNKEQZFSTIMJ-AKWFTNRHSA-N

Description

Description générale

DMT-dA(bz) Pharmadite^® is a Pharmadite^® product line that represents a new class of standard protected DNA phosphoramidites that are designed with highly controlled impurity profiles and exceptional overall purity. Pharmadite phosphoramidites are characterized by their exceptional purity and well-defined impurity profile. In particular, they are essentially free from contaminants that interfere in coupling reactions, such as other nucleosidic or non-nucleosidic phosphoramidites (P(III)-contaminants). All remaining impurities in Pharmadite phosphopramidites, if present, are identified, characterized, and quantified. The impact of any such defined impurities on the synthesis of oligonucleotides is well understood and has been shown to be insignificant.

Application

Pharmadite products fulfill all requirements of starting materials for themanufacture of active pharmaceutical ingredients as defined in the EMEA "Note for guidance on the chemistry of the new active substance," making them suitable building blocks for oligonucleotide drugs.

Autres remarques

Pharmadite phosphoramidites are manufactured in scales of up to multi-hundred kilos, under certified ISO 9001 quality systems.

Informations légales

Pharmadite is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable